NCT07173972View on ClinicalTrials.gov

Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 1, 2028

Study Completion Date

November 1, 2035

Conditions
Soft Tissue Sarcoma (STS)Soft Tissue Sarcoma AdultSoft Tissue Sarcoma of the Trunk and ExtremitiesSynovial SarcomasUndifferentiated Pleomorphic Sarcoma (UPS)MyxofibrosarcomaLeiomyosarcoma (LMS)Pleomorphic LiposarcomaPleomorphic RhabdomyosarcomaLiposarcoma
Interventions
RADIATION

Definitive radiotherapy

The prescribed dose is 56 Gray (Gy) in 16 fractions over 4 weeks (14 Gy per week) with a maximum dose-escalation to the tumor core of 80 Gy (5 Gy per fraction).

Trial Locations (2)

Unknown

Haukeland University Hospital, Bergen

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

Haukeland University Hospital

OTHER

collaborator

St. Olavs Hospital

OTHER

collaborator

University Hospital of North Norway

OTHER

lead

Oslo University Hospital

OTHER